STOCK TITAN
  1. Home
  2. Sec-filings
  3. GPCR
  4. [Form 4] Structure Therapeutics Inc. Insider Trading Activity

FMR LLC funds sell 17,452 Structure Therapeutics (GPCR) ADS at $50.07

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

FMR LLC, a more than 10% owner of Structure Therapeutics Inc., reported indirect sales totaling 17,452 American Depositary Shares on July 22, 2026, in open-market or private transactions at a weighted average $50.07 per ADS via F-Prime funds. Each ADS represents three ordinary shares. FMR and related persons continue to report large indirect holdings, including positions tied to 4,546,674 ordinary shares, and disclaim beneficial ownership of the reported securities.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider FMR LLC
Role 10% Owner
Sold 17,452 shs ($874K)
Type Security Shares Price Value
Sale American Depositary Shares F1, F2 1,367 $50.07 $68K
Sale American Depositary Shares F1, F2 16,085 $50.07 $805K
holding American Depositary Shares F1 -- -- --
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 1,369 shares (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP); American Depositary Shares — 16,086 shares (Indirect, F-Prime Capital Partners Life Sciences Fund VI LP); American Depositary Shares — 4,546,674 shares (Indirect, Shares held by persons and entities whose shares are subject to reporting by the undersigned); Ordinary Shares — 20,502 shares (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP); Ordinary Shares — 241,275 shares (Indirect, F-Prime Capital Partners Life Sciences Fund VI LP)
Footnotes (2)
  1. F1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.
  2. F2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
ADS sold (total) 17,452 American Depositary Shares Total indirect ADS sales by F-Prime funds on 2026-07-22
Weighted average sale price $50.07 per ADS Average of trades between $50.05 and $50.20 per ADS
Sale 1 ADS 1,367 American Depositary Shares Indirect sale by F-Prime Capital Partners Life Sciences Advisors Fund VI LP on 2026-07-22
Sale 2 ADS 16,085 American Depositary Shares Indirect sale by F-Prime Capital Partners Life Sciences Fund VI LP on 2026-07-22
Underlying ordinary shares via ADS 4,546,674 Ordinary Shares Indirect position represented by ADS after the reported transactions
Ordinary shares holding A 20,502 Ordinary Shares Indirect holding by F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary shares holding B 241,275 Ordinary Shares Additional indirect holding by F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares financial
"Reported securities are represented by American Depositary Shares, each of which represents three"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
weighted average price financial
"The price reported for this transaction is the weighted average price of multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial owners financial
"shall not be deemed to be an admission that the undersigned are the beneficial owners"
Beneficial owners are the people or entities that actually enjoy the economic benefits and control of shares or other assets, even when legal title is held by someone else such as a broker, custodian or trustee. Investors pay attention because beneficial owners hold the real voting power, receive dividends and can influence strategy and takeover outcomes — like the driver of a car who uses and maintains it while the bank holds the title — so disclosure shows who truly controls and benefits.
Series B voting common shares financial
"owners, directly or through trusts, of Series B voting common shares of FMR LLC"
Investment Company Act of 1940 regulatory
"may be deemed, under the Investment Company Act of 1940, to form a controlling group"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did FMR LLC report in Structure Therapeutics (GPCR)?
FMR LLC reported indirect sales totaling 17,452 American Depositary Shares of Structure Therapeutics on July 22, 2026. The ADS were sold by affiliated F-Prime funds at a weighted average price of $50.07 per ADS in open-market or private transactions, with substantial indirect holdings remaining.

How many Structure Therapeutics (GPCR) ADS were sold and at what prices?
Affiliated F-Prime funds sold 17,452 ADS of Structure Therapeutics at a weighted average price of $50.07 per ADS. The filing notes this average reflects multiple trades executed between $50.05 and $50.20 per ADS, and detailed trade data is available on request.

What indirect holdings in Structure Therapeutics (GPCR) remain after these Form 4 transactions?
After the reported sales, FMR-related entities continue to report ADS positions representing 4,546,674 ordinary shares of Structure Therapeutics. They also report indirect holdings of 20,502 and 241,275 ordinary shares, in addition to smaller ADS positions for the selling F-Prime funds.

Were the FMR LLC trades in Structure Therapeutics (GPCR) under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not affirmed (left unchecked) for these transactions. It does not state that the sales were executed under a Rule 10b5-1 or other pre-arranged trading plan, nor does it describe any specific trading arrangement.

How are Structure Therapeutics (GPCR) American Depositary Shares structured?
The reported securities are American Depositary Shares, each representing three ordinary shares of Structure Therapeutics. Investors holding ADS indirectly own the underlying ordinary shares, with the depositary bank issuing the ADS as a tradable instrument in place of direct ordinary-share ownership.

Who actually holds the Structure Therapeutics (GPCR) shares reported by FMR LLC?
The ADS and ordinary shares are held indirectly through F-Prime Capital Partners Life Sciences funds and related entities. Remarks state that FMR LLC and related persons, including members of the Johnson family, disclaim beneficial ownership of the securities reported in the Form 4.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FMR LLC
(Last)(First)(Middle)
245 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02210
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)XOther (specify below)
See Remark 1
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares20,502IF-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary Shares241,275IF-Prime Capital Partners Life Sciences Fund VI LP
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
American Depositary Shares(1) (1) (1)Ordinary Shares4,546,6741,515,558IShares held by persons and entities whose shares are subject to reporting by the undersigned
American Depositary Shares(1)07/22/2026S1,367 (1) (1)Ordinary Shares4,101$50.07(2)1,369IF-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares(1)07/22/2026S16,085 (1) (1)Ordinary Shares48,255$50.07(2)16,086IF-Prime Capital Partners Life Sciences Fund VI LP
Explanation of Responses:
1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.
2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Remarks:
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR